Navigating Informed Consent in Clinical Research: Process vs Form
- Mugilraj Sekar
- 3 days ago
- 3 min read

Misunderstanding Informed Consent with a synonymous view
Informed consent is often misunderstood as an one-time act of signing a document. In reality, it is a dynamic, ongoing process that upholds a participant’s autonomy, rights, and safety throughout the course of a clinical trial. Conflating the informed consent process with the informed consent form (ICF) can lead to critical gaps in ethical research conduct.
Too many assume that handing a form to a participant, obtaining a signature, and filing it away meets the ethical and legal requirements. But that signature is just one component. The true spirit of informed consent lies in the transparency, communication, and mutual understanding between research teams and study participants.
Regulatory frameworks such as ICH-GCP, 21 CFR Part 50, and 45 CFR Part 46, along with oversight bodies like the FDA and Institutional Review Boards (IRBs), emphasize that informed consent is a process, not merely a formality. Sponsors and investigators alike share responsibility in ensuring this process is fully honored and documented.
Informed Consent as an Ongoing Process
The informed consent process begins well before a participant signs a form. It typically starts with identifying and screening potential candidates often through a review of electronic medical records (EMRs) to assess eligibility. Once a candidate is identified, the research team reaches out to introduce the study.
From there, a detailed and respectful conversation must occur with the participant (or a Legally Authorized Representative, LAR). The process includes:
Providing the ICF and any other approved recruitment or study materials (e.g., brochures, flyers),
Verbally communicating the study’s purpose, procedures, risks, benefits, and the participant’s rights,
Allowing sufficient time for the participant to read the document, ask questions, and consult with family or healthcare providers if desired,
Ensuring all queries are addressed transparently and honestly.
Only when the participant has voluntarily agreed free of coercion or undue influence does the signature stage begin.
Informed Consent Form: A Document of Understanding and Voluntariness
The Informed Consent Form serves as a legally and ethically binding record. It outlines:
The purpose and nature of the research,
The procedures involved,
Potential risks and benefits,
Alternatives to participation,
Confidentiality measures,
The right to withdraw at any time without penalty.
The form must be signed and dated by the participant and, when required, by an impartial witness. A copy is given to the participant, and a copy is retained in the study records. However, the dialogue continues participants must be re-informed of any new risks or protocol changes as the study progresses, often requiring re-consent.
When Exceptions Apply
There are limited situations in which informed consent may be waived or altered, such as:
Emergency research where immediate intervention is necessary and consent cannot be obtained in time,
Minimal risk studies where obtaining consent is not practicable and a waiver is approved by the IRB,
Retrospective studies using de-identified data where participant contact is not possible.
Each exception must be justified and reviewed by an IRB in accordance with ethical and regulatory guidelines.
Conclusion
Informed consent is more than a signed piece of paper it's a cornerstone of ethical clinical research. By respecting it as a process, we uphold the trust between research participants and the scientific community, ensuring that volunteers participate with full knowledge and free will.
Sources
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2016). Integrated addendum to ICH E6(R1): Guideline for good clinical practice (ICH E6(R2) addendum) [PDF]. ICH. https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf
Food and Drug Administration, U.S. Department of Health and Human Services. (n.d.). 21 CFR Part 50: Protection of Human subjects. In Electronic Code of Federal Regulations. Retrieved August 3, 2025, from https://www.ecfr.gov/current/title-21/chapter‑I/subchapter‑A/part‑50
U.S. Department of Health and Human Services, Office for Human Research Protections. (n.d.). 45 CFR 46: Protection of human subjects. Retrieved August 3, 2025, from https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/index.html
Assessed and Endorsed by the MedReport Medical Review Board